CD105 inhibits transforming growth factor-β-Sma3 signalling

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1337-1345

  Guo, Baoqiang ^a   Slevin, Mark ^b   Li, Chenggang ^a   Parameshwar, Sudeep ^a   Liu, Donghui ^a   Kumar, Pat ^b   Bernabeu, Carmelo ^c   Kumar, Shant ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

CD105; Endoglin; Smad; TGF 1

Indexed keywords

ADENINE; CYTOSINE; ENDOGLIN; GUANINE; LUCIFERASE; LUX BACTERIAL LUCIFERASE; PHORBOL 13 ACETATE 12 MYRISTATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE; SMAD3 PROTEIN; SMAD4 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; INFARCTION; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR; WOUND HEALING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; DNA-BINDING PROTEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE CELLS; PHOSPHORYLATION; RATS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE-1;

EID: 3242716984     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Duff SE, Li C, Garland JM and Kumar S: CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17: 984-992, 2003.
2. Pepper MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8: 21-43, 1997.
3. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P and ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753, 2002.
4. Heldin CH, Miyazono K and ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
5. Massague J: TGF-beta signal transduction. Ann Rev Biochem 67: 753-791, 1998.
6. Cheifetz S, Bellon T, Cales C, Vera, S, Bernabeu C, Massague J and Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
7. Breeken RA, Chenggang Li and Kumar S: Strategies for vascular targeting in tumors. Int J Cancer 100: 123-130, 2002.
8. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S and Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121: 1845-1854, 1995.
9. Oshima M, Oshima H and Taketo MM: TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179: 297-302, 1996.
10. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB and Wendel DP: Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537, 1999.
11. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S and Li E: Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Nat Acad Sci USA 97: 2626-2631, 2000.
12. Fernandez-Ruiz E, St Jacques S, Bellon T, Letarte M and Bernabeu C: Assignment of the human endoglin gene (END) to 9q34->qter. Cytogen Cell Genet 64: 204-207, 1993.
13. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J et al: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351, 1994.
14. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M and Bernabeu C: Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1121, 1996.
15. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L and Bernabeu C: Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 273: 33011-33019, 1998.
16. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14: 55-64, 2000.
17. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT and Wang XF: Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol Cell Biol 17: 7019-7028, 1997.
18. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S and Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF-beta-induciable elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17: 3091-3100, 1998.
19. Kawabata M, Inoue H, Hanyu A, Imamura T and Miyazono K: Smad proteins exist as monomers in vivo. EMBO J 17: 4056-4065, 1998.
20. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA and Letarte M: Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 50: 265-276, 1997.
21. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF and Massague J: TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014, 1992.
22. Atfi A, Djelloul S, Chastre E, Davis R and Gespach C: Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem 272: 1429-1432, 1997.
23. Hocevar BA, Brown TL and Howe PH: TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 18: 1345-1356, 1999.
24. Behrens A, Sibilia M and Wagner EF: Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 21: 326-329, 1999.
25. Dennler S, Prunier C, Ferrand N, Gauthier JM and Atfi A: c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity. J Biol Chem 275: 28858-28865, 2000.
26. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P and Miyazono K: Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 2001, 1995.
27. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM and Wang XF: Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci USA 96: 4844-4849, 1999.
28. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A and Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 277: 29197-29209, 2002.
29. Diez-Marques L, Ortega-Velazquez R, Langa C, Rodriguez-Barbero A, Lopez-Novoa JM, Lamas S and Bernabeu C: Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta 1587: 36-44, 2002.
30. Chen SJ, Yuan W, Lo S, Trojanowska M and Varga J: Interaction of smad3 with a proximal smad-binding element of the human alpha2 (I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 83: 381-392, 2000.
31. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, Chen Y, Venstrom K, Dou X, Ponticos M, Black C, Bernabeu C, Jackman JK, Findell PR and Connolly MK: Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 46: 1857-1865, 2002.
32. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM and Leask A: CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276: 10594-10601, 2001.
33. McGaha TL, Phelps RG, Spiera H and Bona C: Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118: 461-470, 2002.
34. Luo K and Lodish HF: Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues. EMBO J 16: 1970-1981, 1997.
35. Caniggia I, Taylor CV, Ritchie JW, Lye SJ and Letarte M: Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology 138: 4977-4988, 1997.
36. Mazars A, Tournigand C, Mollat P, Prunier C, Ferrand N, Bourgeade MF, Gespach C and Atfi A: Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta. Oncogene 9: 1277-1287, 2000.
37. Angel P, Hattori K, Smeal T and Karin M: The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55: 875-885, 1988.
38. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M and Davis RJ: JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037, 1994.
39. Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts AB and Mauviel A: Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. Oncogene 20: 3332-3340, 2001.
40. Li C, Issa R, Kumar P, Hampsion IN, Bernabeu C and Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 16: 738-747, 2003.